Health Tech Capitol | HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses
17084
post-template-default,single,single-post,postid-17084,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

21 Sep HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

Posted at 10:59h in Uncategorized by
0 Likes

HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne’s technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma in chest computed tomography (CT) scans. Researchers analyzed radiomic biomarkers to predict Overall Survival (OS) and Progression Free Survival (PFS) time.

To perform the study, researchers selected 74 patients with histologically confirmed lung cancer who underwent immunotherapy and compared them with 50 patients with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy.

Read more at Imagine Technology News

No Comments

Sorry, the comment form is closed at this time.